ArticleTranslational lung cancer research2026
Neoadjuvant chemoimmunotherapy in resected stage III non-small-cell lung cancer: real-world data from a nationwide registry.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoimmunotherapy is increasingly used in resectable stage III non-small-cell lung cancer. The objective was to compare oncological effectiveness, surgical complexity and perioperative safety of neoadjuvant chemoimmunotherapy compared to chemotherapy. Methods: A multicentre cohort study was performed within the Registry of the Spanish Society of Thoracic Surgery. Consecutive patients with stage III non-small-cell lung cancer treated with chemoimmunotherapy or chemotherapy followed by anatomical resection (January 2023-April 2025) were analysed (114 patients: chemoimmunotherapy 77; chemotherapy 37). Oncological variables were pathological complete response, downstaging and complete resection (International Association for the Study of Lung Cancer criteria). Surgical and perioperative outcomes were compared, including complications and mortality. Propensity-score matching was used to reduce confounding and outcomes were compared using paired tests. Results: After matching, 68 patients remained (34 pairs). Chemoimmunotherapy yielded higher pathological complete response [38% Conclusions: Neoadjuvant chemoimmunotherapy for resected stage III non-small-cell lung cancer improved pathological complete response, downstaging and complete resection versus chemotherapy, at the expense of longer operations and higher morbidity, without an increase in severe complications or early mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.